195 related articles for article (PubMed ID: 31626289)
21. Targeted fusion analysis can aid in the classification and treatment of pediatric glioma, ependymoma, and glioneuronal tumors.
Lake JA; Donson AM; Prince E; Davies KD; Nellan A; Green AL; Mulcahy Levy J; Dorris K; Vibhakar R; Hankinson TC; Foreman NK; Ewalt MD; Kleinschmidt-DeMasters BK; Hoffman LM; Gilani A
Pediatr Blood Cancer; 2020 Jan; 67(1):e28028. PubMed ID: 31595628
[TBL] [Abstract][Full Text] [Related]
22. Recurrent EP300-BCOR Fusions in Pediatric Gliomas With Distinct Clinicopathologic Features.
Torre M; Meredith DM; Dubuc A; Solomon DA; Perry A; Vasudevaraja V; Serrano J; Snuderl M; Ligon KL; Alexandrescu S
J Neuropathol Exp Neurol; 2019 Apr; 78(4):305-314. PubMed ID: 30816933
[TBL] [Abstract][Full Text] [Related]
23. Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations.
Reinhardt A; Stichel D; Schrimpf D; Sahm F; Korshunov A; Reuss DE; Koelsche C; Huang K; Wefers AK; Hovestadt V; Sill M; Gramatzki D; Felsberg J; Reifenberger G; Koch A; Thomale UW; Becker A; Hans VH; Prinz M; Staszewski O; Acker T; Dohmen H; Hartmann C; Mueller W; Tuffaha MSA; Paulus W; Heß K; Brokinkel B; Schittenhelm J; Monoranu CM; Kessler AF; Loehr M; Buslei R; Deckert M; Mawrin C; Kohlhof P; Hewer E; Olar A; Rodriguez FJ; Giannini C; NageswaraRao AA; Tabori U; Nunes NM; Weller M; Pohl U; Jaunmuktane Z; Brandner S; Unterberg A; Hänggi D; Platten M; Pfister SM; Wick W; Herold-Mende C; Jones DTW; von Deimling A; Capper D
Acta Neuropathol; 2018 Aug; 136(2):273-291. PubMed ID: 29564591
[TBL] [Abstract][Full Text] [Related]
24. Molecular and clinicopathologic features of gliomas harboring NTRK fusions.
Torre M; Vasudevaraja V; Serrano J; DeLorenzo M; Malinowski S; Blandin AF; Pages M; Ligon AH; Dong F; Meredith DM; Nasrallah MP; Horbinski C; Dahiya S; Ligon KL; Santi M; Ramkissoon SH; Filbin MG; Snuderl M; Alexandrescu S
Acta Neuropathol Commun; 2020 Jul; 8(1):107. PubMed ID: 32665022
[TBL] [Abstract][Full Text] [Related]
25. TPD52L1-ROS1, a new ROS1 fusion variant in lung adenosquamous cell carcinoma identified by comprehensive genomic profiling.
Zhu VW; Upadhyay D; Schrock AB; Gowen K; Ali SM; Ou SH
Lung Cancer; 2016 Jul; 97():48-50. PubMed ID: 27237027
[TBL] [Abstract][Full Text] [Related]
26. ROS1 fusions in cancer: a review.
Uguen A; De Braekeleer M
Future Oncol; 2016 Aug; 12(16):1911-28. PubMed ID: 27256160
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of Crizotinib Treatment in a Patient With Unresectable GOPC-ROS1 Fusion Agminated Spitz Nevi.
Robertson SJ; Orme L; Teixeira R; Shamassi M; Newell F; Patch AM; Yeh I; Gard G; Wilmott J; Jackett L; LeBoit P; Fellowes A; MacArthur G; Fox S; Hayward NK; Bastian B; Scolyer R; Waddell N; Penington A; Shackleton M
JAMA Dermatol; 2021 Jul; 157(7):836-841. PubMed ID: 34076666
[TBL] [Abstract][Full Text] [Related]
28. Genetic alterations in uncommon low-grade neuroepithelial tumors: BRAF, FGFR1, and MYB mutations occur at high frequency and align with morphology.
Qaddoumi I; Orisme W; Wen J; Santiago T; Gupta K; Dalton JD; Tang B; Haupfear K; Punchihewa C; Easton J; Mulder H; Boggs K; Shao Y; Rusch M; Becksfort J; Gupta P; Wang S; Lee RP; Brat D; Peter Collins V; Dahiya S; George D; Konomos W; Kurian KM; McFadden K; Serafini LN; Nickols H; Perry A; Shurtleff S; Gajjar A; Boop FA; Klimo PD; Mardis ER; Wilson RK; Baker SJ; Zhang J; Wu G; Downing JR; Tatevossian RG; Ellison DW
Acta Neuropathol; 2016 Jun; 131(6):833-45. PubMed ID: 26810070
[TBL] [Abstract][Full Text] [Related]
29. High-grade glioneuronal tumor with an ARHGEF2-NTRK1 fusion gene.
Kurozumi K; Nakano Y; Ishida J; Tanaka T; Doi M; Hirato J; Yoshida A; Washio K; Shimada A; Kohno T; Ichimura K; Yanai H; Date I
Brain Tumor Pathol; 2019 Jul; 36(3):121-128. PubMed ID: 31011918
[TBL] [Abstract][Full Text] [Related]
30. Comprehensive Genomic Profiling of 282 Pediatric Low- and High-Grade Gliomas Reveals Genomic Drivers, Tumor Mutational Burden, and Hypermutation Signatures.
Johnson A; Severson E; Gay L; Vergilio JA; Elvin J; Suh J; Daniel S; Covert M; Frampton GM; Hsu S; Lesser GJ; Stogner-Underwood K; Mott RT; Rush SZ; Stanke JJ; Dahiya S; Sun J; Reddy P; Chalmers ZR; Erlich R; Chudnovsky Y; Fabrizio D; Schrock AB; Ali S; Miller V; Stephens PJ; Ross J; Crawford JR; Ramkissoon SH
Oncologist; 2017 Dec; 22(12):1478-1490. PubMed ID: 28912153
[TBL] [Abstract][Full Text] [Related]
31. CD74-ROS1 fusion transcripts in resected non-small cell lung carcinoma.
Matsuura S; Shinmura K; Kamo T; Igarashi H; Maruyama K; Tajima M; Ogawa H; Tanahashi M; Niwa H; Funai K; Kohno T; Suda T; Sugimura H
Oncol Rep; 2013 Oct; 30(4):1675-80. PubMed ID: 23877438
[TBL] [Abstract][Full Text] [Related]
32. [Tyrosine kinase receptor gene fusion: A series of four cases of infantile-type hemispheric glioma].
Sourty B; Basset L; Michalak S; Colin E; Zidane-Marinnes M; Delion M; de Carli E; Rousseau A
Ann Pathol; 2023 Nov; 43(6):462-474. PubMed ID: 37635016
[TBL] [Abstract][Full Text] [Related]
33. Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion.
Rimkunas VM; Crosby KE; Li D; Hu Y; Kelly ME; Gu TL; Mack JS; Silver MR; Zhou X; Haack H
Clin Cancer Res; 2012 Aug; 18(16):4449-57. PubMed ID: 22661537
[TBL] [Abstract][Full Text] [Related]
34. Isomorphic diffuse glioma is a morphologically and molecularly distinct tumour entity with recurrent gene fusions of MYBL1 or MYB and a benign disease course.
Wefers AK; Stichel D; Schrimpf D; Coras R; Pages M; Tauziède-Espariat A; Varlet P; Schwarz D; Söylemezoglu F; Pohl U; Pimentel J; Meyer J; Hewer E; Japp A; Joshi A; Reuss DE; Reinhardt A; Sievers P; Casalini MB; Ebrahimi A; Huang K; Koelsche C; Low HL; Rebelo O; Marnoto D; Becker AJ; Staszewski O; Mittelbronn M; Hasselblatt M; Schittenhelm J; Cheesman E; de Oliveira RS; Queiroz RGP; Valera ET; Hans VH; Korshunov A; Olar A; Ligon KL; Pfister SM; Jaunmuktane Z; Brandner S; Tatevossian RG; Ellison DW; Jacques TS; Honavar M; Aronica E; Thom M; Sahm F; von Deimling A; Jones DTW; Blumcke I; Capper D
Acta Neuropathol; 2020 Jan; 139(1):193-209. PubMed ID: 31563982
[TBL] [Abstract][Full Text] [Related]
35. ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features.
Pan Y; Zhang Y; Li Y; Hu H; Wang L; Li H; Wang R; Ye T; Luo X; Zhang Y; Li B; Cai D; Shen L; Sun Y; Chen H
Lung Cancer; 2014 May; 84(2):121-6. PubMed ID: 24629636
[TBL] [Abstract][Full Text] [Related]
36. A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer.
Lira ME; Choi YL; Lim SM; Deng S; Huang D; Ozeck M; Han J; Jeong JY; Shim HS; Cho BC; Kim J; Ahn MJ; Mao M
J Mol Diagn; 2014 Mar; 16(2):229-43. PubMed ID: 24418728
[TBL] [Abstract][Full Text] [Related]
37. Expression of C-terminal ALK, RET, or ROS1 in lung cancer cells with or without fusion.
Furugaki K; Mochizuki M; Kohno M; Shu S; Harada N; Yoshimura Y
BMC Cancer; 2019 Apr; 19(1):301. PubMed ID: 30943926
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of Crizotinib among Different Types of ROS1 Fusion Partners in Patients with ROS1-Rearranged Non-Small Cell Lung Cancer.
Li Z; Shen L; Ding D; Huang J; Zhang J; Chen Z; Lu S
J Thorac Oncol; 2018 Jul; 13(7):987-995. PubMed ID: 29704675
[TBL] [Abstract][Full Text] [Related]
39. [Detection of ALK, ROS1 and RET fusion genes in non-small cell lung cancer patients and its clinicopathologic correlation].
Zhong S; Zhang H; Bai D; Gao D; Zheng J; Ding Y
Zhonghua Bing Li Xue Za Zhi; 2015 Sep; 44(9):639-43. PubMed ID: 26705279
[TBL] [Abstract][Full Text] [Related]
40. ROS1 receptor tyrosine kinase, a druggable target, is frequently overexpressed in non-small cell lung carcinomas via genetic and epigenetic mechanisms.
Lee HJ; Seol HS; Kim JY; Chun SM; Suh YA; Park YS; Kim SW; Choi CM; Park SI; Kim DK; Kim YH; Jang SJ
Ann Surg Oncol; 2013 Jan; 20(1):200-8. PubMed ID: 22915320
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
